{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-016294","form_type":"8-K","ticker":"FBIO","cik":"0001429260","company_name":"Fortress Biotech, Inc.","filed_at":"2024-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.431267+00:00","generated_at":"2026-05-29T02:51:00.547286+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"FDA approves Fortress subsidiary Checkpoint's UNLOXCYT for advanced cSCC","bullets":["FDA approved UNLOXCYT (cosibelimab-ipdl) for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) in adults not candidates for curative surgery/radiation.","UNLOXCYT is the first and only PD-L1 blocking antibody approved for this indication.","Approval based on objective response rates and duration of response from Study CK-301-101 (NCT03212404).","Checkpoint Therapeutics is a majority-controlled subsidiary of Fortress Biotech, Inc."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-016294","json":"https://secwatch.observer/filing/0001558370-24-016294.json","markdown":"https://secwatch.observer/filing/0001558370-24-016294.md","text":"https://secwatch.observer/filing/0001558370-24-016294.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1429260/000155837024016294/0001558370-24-016294-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1429260/000155837024016294/fbio-20241213x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T02:51:00.547286+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}